{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:58:10Z","timestamp":1790024290229,"version":"4.0.1"},"reference-count":80,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Post-transplant lymphoproliferative disease (PTLD) is a fatal complication of hematopoietic cell transplantation (HCT) associated with the Epstein\u2013Barr virus (EBV). Multiple factors such as transplant type, graft-versus-host disease (GVHD), human leukocyte antigens (HLA) mismatch, patient age, and T-lymphocyte-depleting treatments increase the risk of PTLD. EBV reactivation in hematopoietic cell transplant recipients is monitored through periodic quantitative polymerase chain reaction (Q-PCR) tests. However, substantial uncertainty persists regarding the clinically significant EBV levels for these patients. Guidelines recommend initiating EBV monitoring no later than four weeks post-HCT and conducting it weekly. Pre-emptive therapies, such as the reduction of immunosuppressive therapy and the administration of rituximab to treat EBV viral loads are also suggested. In this study, we investigated the occurrence of EBV-PTLD in 546 HCT recipients, focusing on the clinical manifestations and risk factors associated with the disease. We managed to identify 67,150 viral genomic copies\/mL as the cutoff point for predicting PTLD, with 80% sensitivity and specificity. Among our cohort, only 1% of the patients presented PTLD. Anti-thymocyte globulin (ATG) and GVHD were independently associated with lower survival rates and higher treatment-related mortality. According to our findings, prophylactic measures including regular monitoring, pre-emptive therapy, and supportive treatment against infections can be effective in preventing EBV-related complications. This study also recommends conducting EBV monitoring at regular intervals, initiating pre-emptive therapy when viral load increases, and identifying factors that increase the risk of PTLD. Our study stresses the importance of frequent and careful follow-ups of post-transplant complications and early intervention in order to improve survival rates and reduce mortality.<\/jats:p>","DOI":"10.3390\/ijms242216029","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T10:52:47Z","timestamp":1699354367000},"page":"16029","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pre-Emptive Use of Rituximab in Epstein\u2013Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes"],"prefix":"10.3390","volume":"24","author":[{"given":"Apostolia","family":"Papalexandri","sequence":"first","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vardi","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2919-5179","authenticated-orcid":false,"given":"Nikolaos","family":"Kotsiou","sequence":"additional","affiliation":[{"name":"2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2008-7954","authenticated-orcid":false,"given":"Christos","family":"Demosthenous","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natassa","family":"Constantinou","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasoula","family":"Touloumenidou","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiota","family":"Zerva","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini","family":"Kika","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Iskas","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Batsis","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Mallouri","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Yannaki","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4384-9031","authenticated-orcid":false,"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[{"name":"Hematology Department, BMT Unit, General Hospital \u201cGeorge Papanicolaou\u201d, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"ref_2","first-page":"1059","article-title":"The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation","volume":"91","author":"Sundin","year":"2006","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein\u2013Barr Virus Infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1038\/cti.2015.1","article-title":"Infectious mononucleosis","volume":"4","author":"Balfour","year":"2015","journal-title":"Clin. Transl. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrc1452","article-title":"Epstein\u2013Barr virus: 40 years on","volume":"4","author":"Young","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","first-page":"2603","article-title":"Epstein-Barr Virus and Its Replication","volume":"Volume 2","author":"Knipe","year":"2007","journal-title":"Fields Virology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1182\/blood-2010-05-285791","article-title":"Lymphomas differ in their dependence on Epstein-Barr virus","volume":"117","author":"Vereide","year":"2011","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1182\/blood-2015-08-665000","article-title":"Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event","volume":"126","author":"Burns","year":"2015","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/MOT.0b013e3283186ba9","article-title":"Epstein\u2013Barr virus, rapamycin, and host immune responses","volume":"13","author":"Krams","year":"2008","journal-title":"Curr. Opin. Organ Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/hon.751","article-title":"Post-transplant lymphoproliferative disorders: Molecular basis of disease histogenesis and pathogenesis","volume":"23","author":"Capello","year":"2005","journal-title":"Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0092-8674(91)90007-L","article-title":"Induction of bcl-2 expression by epstein-barr virus latent membrane protein 1 protects infected B cells from programmed cell death","volume":"65","author":"Henderson","year":"1991","journal-title":"Cell"},{"key":"ref_12","unstructured":"Swerdlow, S.H., Webber, S.A., and Ferry, J.A. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, AARC."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","article-title":"Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41409-019-0548-7","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: A comprehensive review from pathogenesis to forthcoming treatment modalities","volume":"55","author":"Bazarbachi","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.bmt.1704089","article-title":"High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic stem cell transplantation as a consequence of intensive immunosuppressive treatment","volume":"32","author":"Juvonen","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3324\/haematol.2013.087338","article-title":"Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation","volume":"99","author":"Uhlin","year":"2013","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1080\/10428190601059837","article-title":"EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning","volume":"48","author":"Cohen","year":"2007","journal-title":"Leuk. Lymphoma"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1034\/j.1399-3062.2001.003002070.x","article-title":"Identifying the patient at risk for post-transplant lymphoproliferative disorder","volume":"3","author":"Cockfield","year":"2001","journal-title":"Transpl. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"604.e1","DOI":"10.1016\/j.cmi.2015.02.002","article-title":"Current preventive strategies and management of Epstein\u2013Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey","volume":"21","author":"Manuel","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.bmt.1701554","article-title":"B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: Risk factors, treatment and outcome","volume":"23","author":"Gross","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/00365540600978906","article-title":"Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction","volume":"39","author":"Kinch","year":"2007","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1182\/blood-2006-03-011791","article-title":"Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation","volume":"108","author":"Brunstein","year":"2006","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-Transplantation Lymphoproliferative Disorders in Adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11060-011-0739-6","article-title":"Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation","volume":"107","author":"Lieberman","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-6143.2008.02514.x","article-title":"Interlaboratory Comparison of Epstein-Barr Virus Viral Load Assays","volume":"9","author":"Preiksaitis","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Dharnidharka, V.R., Green, M., and Webber, S. (2010). Post-Transplant Lymphoproliferative Disorders, Springer.","DOI":"10.1007\/978-3-642-01653-0"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2010.03.016","article-title":"EBV viral load detection in clinical virology","volume":"48","author":"Preiksaitis","year":"2010","journal-title":"J. Clin. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3324\/haematol.2016.144428","article-title":"Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines","volume":"101","author":"Styczynski","year":"2016","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e00146-18","DOI":"10.1128\/JCM.00146-18","article-title":"Quantitative Inference of Commutability for Clinical Viral Load Testing","volume":"56","author":"Tang","year":"2018","journal-title":"J. Clin. Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jmoldx.2016.02.002","article-title":"Comparative Evaluation of Four Real-Time PCR Methods for the Quantitative Detection of Epstein-Barr Virus from Whole Blood Specimens","volume":"18","author":"Buelow","year":"2016","journal-title":"J. Mol. Diagn."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/ctr.12473","article-title":"Multicenter comparison of laboratory performance in cytomegalovirus and Epstein-Barr virus viral load testing using international standards","volume":"28","author":"Rychert","year":"2014","journal-title":"Clin. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood.V98.4.972","article-title":"Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell\u2013depleted SCT","volume":"98","author":"Meijer","year":"2001","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/TP.0b013e31819f1c49","article-title":"Preemptive Management of Epstein-Barr Virus Reactivation After Hematopoietic Stem-Cell Transplantation","volume":"87","author":"Ahmad","year":"2009","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.2011.08855.x","article-title":"Pre-emptive rituximab based on viraemia and T cell reconstitution: A highly effective strategy for the prevention of Epstein\u2013Barr virus-associated lymphoproliferative disease following stem cell transplantation","volume":"155","author":"Worth","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bjh.15263","article-title":"Management of post-transplant lymphoproliferative disorders","volume":"182","author":"DeStefano","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1399-3062.2008.00313.x","article-title":"Comparison of serum and whole blood levels of cytomegalovirus and Epstein-Barr virus DNA","volume":"10","author":"Olofsson","year":"2008","journal-title":"Transpl. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder\u2605","volume":"11","author":"Reshef","year":"2011","journal-title":"Am. J. Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1399-3062.2009.00411.x","article-title":"Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: A comprehensive review of reported cases","volume":"11","author":"Styczynski","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/tid.12618","article-title":"Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy","volume":"18","author":"Raberahona","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/s41409-020-0928-z","article-title":"Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody","volume":"55","author":"Chang","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bbmt.2010.10.003","article-title":"Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation","volume":"17","author":"Coppoletta","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/tid.12061","article-title":"Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab","volume":"15","author":"Patriarca","year":"2013","journal-title":"Transpl. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1080\/10428190600908349","article-title":"Single agent efficacy of rituximab in childhood immunosuppression related lymphoproliferative disease: A United Kingdom Children\u2019s Cancer Study Group (UKCCSG) retrospective review","volume":"47","author":"Messahel","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/MOH.0000000000000083","article-title":"Epstein\u2013Barr virus lymphoproliferative disease after hematopoietic stem cell transplant","volume":"21","author":"Rouce","year":"2014","journal-title":"Curr. Opin. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.bbmt.2010.08.007","article-title":"Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients","volume":"17","author":"Reddy","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.trim.2015.12.002","article-title":"Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological\u2013immunological monitoring of EBV infection, prompt diagnosis and early treatment","volume":"34","author":"Chiereghin","year":"2016","journal-title":"Transpl. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41409-019-0699-6","article-title":"Pre-emptive rituximab treatment for Epstein\u2013Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: A comparative study for immune recovery and clinical outcomes","volume":"55","author":"Stocker","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.blre.2013.07.002","article-title":"Anti-CD20 monoclonal antibodies: Beyond B-cells","volume":"27","author":"Avivi","year":"2013","journal-title":"Blood Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1080\/10428194.2017.1365860","article-title":"Long-term outcome of Epstein\u2013Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT","volume":"59","author":"Kinch","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"773853","DOI":"10.3389\/fimmu.2021.773853","article-title":"Case Report: Persistent Hypogammaglobulinemia More Than 10 Years After Rituximab Given Post-HSCT","volume":"12","author":"Luterbacher","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1097\/TP.0b013e3182664042","article-title":"Increased Infection Rate After Preemptive Rituximab Treatment for Epstein-Barr Virus Reactivation After Allogeneic Hematopoietic Stem-Cell Transplantation","volume":"94","author":"Petropoulou","year":"2012","journal-title":"Transplantation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1111\/j.1600-6143.2007.01823.x","article-title":"Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation","volume":"7","author":"Comoli","year":"2007","journal-title":"Am. J. Transplant."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1200\/JCO.20.01709","article-title":"Adoptive T-Cell Therapy for Epstein-Barr Virus\u2013Related Lymphomas","volume":"39","author":"Heslop","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jcyt.2013.11.010","article-title":"The time is now: Moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care","volume":"16","author":"Saglio","year":"2014","journal-title":"Cytotherapy"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1182\/blood-2009-08-236356","article-title":"Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells","volume":"115","author":"Moosmann","year":"2010","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/bjh.16053","article-title":"T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy","volume":"187","author":"Keller","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1097\/HS9.0000000000000809","article-title":"Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond","volume":"7","author":"Papadopoulou","year":"2023","journal-title":"Hemasphere"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41409-020-01145-1","article-title":"Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease\u2014A single center case series","volume":"56","author":"Luttwak","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e13861","DOI":"10.1111\/petr.13861","article-title":"Treatment of post-transplant lymphoproliferative disorder (PTLD) in a heart transplant recipient with chimeric antigen receptor T-cell therapy","volume":"25","author":"Dang","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"709370","DOI":"10.3389\/fonc.2021.709370","article-title":"Case Report: Successful Chimeric Antigen Receptor T Cell Therapy in Haploidentical-Allogeneic Stem Cell Transplant Patients with Post-Transplant Lymphoproliferative Disorder","volume":"11","author":"Yan","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2008-01-132167","article-title":"Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder","volume":"111","author":"Portell","year":"2008","journal-title":"Blood"},{"key":"ref_68","first-page":"945","article-title":"Lenalidomide monotherapy leads to a complete remission in refractory B-cell post-transplant lymphoproliferative disorder","volume":"57","author":"Tzankov","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V118.21.4947.4947","article-title":"Bortezomib and Rituximab in the Treatment of Post-Transplant Lymphoproliferative Disorders","volume":"118","author":"Blaes","year":"2011","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/CCO.0b013e3283499c37","article-title":"Bortezomib-induced Epstein\u2013Barr virus and Kaposi sarcoma herpesvirus lytic gene expression","volume":"23","author":"Reid","year":"2011","journal-title":"Curr. Opin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jcyt.2018.02.367","article-title":"Epstein-barr virus DNAemia monitoring for the management of post-transplant lymphoproliferative disorder","volume":"20","author":"Kalra","year":"2018","journal-title":"Cytotherapy"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/bmt.2014.298","article-title":"Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab","volume":"50","author":"Castillo","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_73","first-page":"284","article-title":"Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation","volume":"44","author":"Chen","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"D\u00fcver, F., Wei\u00dfbrich, B., Eyrich, M., W\u00f6lfl, M., Schlegel, P.G., and Wiegering, V. (2020). Viral reactivations following hematopoietic stem cell transplantation in pediatric patients\u2014A single center 11-year analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0228451"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcv.2017.10.016","article-title":"Epstein-Barr virus DNA load kinetics analysis in allogeneic hematopoietic stem cell transplant recipients: Is it of any clinical usefulness?","volume":"97","author":"Solano","year":"2017","journal-title":"J. Clin. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.clml.2017.06.008","article-title":"The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies","volume":"17","author":"Sakellari","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1097\/HS9.0000000000000487","article-title":"Endothelial and Complement Activation as Predictors of Survival in Adult Allogeneic Hematopoietic Cell Transplantation","volume":"5","author":"Gavriilaki","year":"2020","journal-title":"Hemasphere"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_80","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:18:37Z","timestamp":1760131117000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/22\/16029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":80,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["ijms242216029"],"URL":"https:\/\/doi.org\/10.3390\/ijms242216029","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]}}}